
Commentary|Videos|May 29, 2025
Going for GOLD: Updated COPD Guidelines with Gerard Criner, MD
Author(s)Albert Rizzo, MD, Gerard Criner, MD
Fact checked by: Victoria Johnson
Gerard Criner, MD, spells out GOLD improvements, from interventions like smoking cessation and pulmonary rehabilitation to the heightened importance of spirometry for diagnosis.
Advertisement
Advertisement
Chronic obstructive pulmonary disease (COPD) remains a major public health challenge, affecting over 14 million adults in the U.S.—with many more likely undiagnosed—and ranking as the sixth leading cause of death nationally and fourth globally. As of 2024, more than half of diagnosed U.S. patients are women, with higher prevalence seen in rural areas, and while tobacco smoking accounts for over 70% of COPD cases in high-income countries, household air pollution and occupational exposures drive a significant burden worldwide.
Related to this article

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.
Advertisement
Advertisement

